F3 and COVID-19: Notably, the extent of coagulation activation, implicated in the relatively high incidence of thromboembolic complications in COVID-19,23 was not different between CAP groups (tissue factor, D-dimer), in spite of evidence of increased systemic inflammation in COVID-19 (ferritin).